Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.
Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.
Abstract: Cleansing compositions can include hinokitiol; and a 2-pyridinol N-oxide material; wherein the ratio by weight of the 2-pyridinol N-oxide material to the hinokitiol is about 1:4 to about 2:1 and the combination of the 2-pyridinol N-oxide material and hinokitiol includes about 9 ppm or more by weight of the cleansing composition.
Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the formula: L1-L2-LP-NH—(CH2)n1-La-Lb-Lc or -L1-L2-LP- wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the terminal Lc or LP with the nitrogen atom of the amino group at position 1 as the connecting position.
Abstract: An object of the present invention is to provide a freeze-dried aripiprazole powder formulation that exhibits good dispersibility and is easily dispersed into a homogenous suspension when reconstituted with water. The present invention provides a freeze-dried aripiprazole formulation obtained by a process comprising the steps of spraying for freezing an aripiprazole suspension containing (I) aripiprazole, (II) a vehicle for the aripiprazole, and (III) water for injection, and drying.
Abstract: According to the subject invention, there is disclosed, a dosage and packaging configuration which includes the use of color-coded pre-filled syringes and vials to fill and refill infusion systems with existing and new dosage forms of intrathecal baclofen.
Abstract: A polypeptide having an amino acid sequence corresponding to a binding domain of a botulinum toxin is described. The polypeptide modulates expression of genes involved in, for example, collagen production and extra cellular matrix organization, and finds use, therefore in modulating skin quality attributes such as elasticity, firmness etc. Moreover, the polypeptide inhibits lipogenesis in specialized cells and finds use, therefore, in reducing skin oiliness, which is frequently observed in skin tissue afflicted with large pores and acne. Nucleic acids encoding the polypeptide, as well as vectors, host cells, and systems comprising the nucleic acids, are further described.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
October 19, 2021
Assignee:
Alleergan, Inc.
Inventors:
Birgitte P S Jacky, Amy Brideau-Andersen, Hui You, Shiazah Z. Malik, Donald E. Frail, Mitchell F. Brin
Abstract: A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.
Type:
Grant
Filed:
November 22, 2013
Date of Patent:
October 19, 2021
Assignee:
EnGenlC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: The present invention is directed to processes for extracting IgG from an unused waste precipitate produced during normal plasma fractionation processes via a separate fractionation process, thereby increasing the overall yield of IgG from blood plasma.
Abstract: The invention relates to the field of protecting plants against pests, and more particularly to a method of protecting plants against pests, which can be used for industrial and scientific purposes, in agriculture, horticulture and forestry. The method of protecting plants against pests according to the present invention comprises applying a biologically active preparation pre-activated in an aqueous medium to a plant, the preparation comprising microcontainers and a biological insecticide, wherein the microcontainers are made from a polymeric material in the form of a hollow receptacle with at least one opening, via which the biological insecticide is placed inside the microcontainers. The invention also provides a microcontainer and a preparation for realisation of the stated method. Furthermore, the invention provides methods for producing a microcontainer and the aforementioned preparation.
Type:
Grant
Filed:
August 17, 2015
Date of Patent:
October 12, 2021
Assignee:
OBSHCHESTVO S OGRANITCHENNOY OTVETSTVENNOST'YU “FUNGIPAK”
Inventors:
Oleg Viktorovitch Fokin, Viktor Vladimirovitch Seregin
Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
Type:
Grant
Filed:
June 28, 2019
Date of Patent:
October 5, 2021
Assignee:
Byondis B.V.
Inventors:
Gerardus Joseph Andreas Ariaans, Rudy Gerardus Elisabeth Coumans
Abstract: The present invention provides methods for directly transferring a recombinant polynucleotide of interest from the chromosome of a prokaryotic donor cell to the chromosome of a prokaryotic recipient cell of another species, wherein the polynucleotide of interest comprises at least one coding sequence of interest, preferably one gene of interest and a selectable marker, wherein said polynucleotide of interest in the chromosome of the donor cell is flanked on each side by a polynucleotide region derived from the chromosome of the recipient cell, and wherein the flanking polynucleotide regions are of sufficient size and sequence identity to allow double homologous recombination with the corresponding regions in the chromosome of the recipient cell.
Type:
Grant
Filed:
July 4, 2014
Date of Patent:
September 28, 2021
Assignee:
Novozymes, A/S
Inventors:
Michael Dolberg Rasmussen, Gitte Bak Poulsen
Abstract: The invention relates to an orally administrable chewable composition in unit dosage form comprising an oil-in-water emulsion in which the aqueous phase is gelled and in which the oil phase comprises a physiologically tolerable unsaturated fatty acid ester.
Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.
Type:
Grant
Filed:
March 13, 2020
Date of Patent:
September 7, 2021
Assignees:
The Board of Trustees of the Leland Standford Junior University, BOLT BIOTHERAPEUTICS, INC.
Inventors:
Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
Abstract: The subject of the present application is an antiperspirant composition for personal body care having improved stability of the suspension contained, which contains a mixture of at least one oil, rice starch, at least one hydrophobically modified clay mineral and an antiperspirant active substance in the form of spherical particles.
Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
Type:
Grant
Filed:
June 28, 2019
Date of Patent:
August 31, 2021
Assignee:
Byondis B.V.
Inventors:
Gerardus Joseph Andreas Ariaans, Rudy Gerardus Elisabeth Coumans
Abstract: Disclosed are oral care compositions, for example dentifrice compositions, comprising an orally acceptable vehicle, metal oxide particles having an average particle size of no greater than a dentin tubule and a polymeric adherent material for adhering the metal oxide particles in the dentin tubule. The metal oxide particles have a median particle size of 5 microns or less, and may comprise zinc oxide.
Type:
Grant
Filed:
August 27, 2019
Date of Patent:
August 31, 2021
Assignee:
Colgate-Palmolive Company
Inventors:
Venda Porter Maloney, André Michelle Morgan, Michael Prencipe, Sarita Vera Mello
Abstract: The present disclosure relates to anhydrous cosmetic compositions which contain a combination of a strongly swelling and a low-swelling water-absorbing component, an odor-absorbing component and a deodorant active ingredient. These compositions have an outstanding deodorizing effect and improved sensory features and additionally result in a minimization of sweat spots on textiles. Furthermore, the present disclosure relates to a cosmetic product containing these anhydrous compositions and the use of this composition or product for reduction of the body odor released by perspiration. Finally, the present disclosure relates to the use a strongly swelling water-absorbing component in combination with an odor-absorbing component to improve the sensory characteristics of anhydrous deodorant compositions.
Type:
Grant
Filed:
December 18, 2017
Date of Patent:
August 24, 2021
Assignee:
Henkel AG & Co. KGaA
Inventors:
Bernhard Banowski, Marcus Claas, Angela Mueller